Multiple Myeloma | Pharmacor | G7 | 2015

The 2014 multiple myeloma market garnered impressive sales despite its relatively low incidence compared with other oncology markets with similar revenues. Significant achievements in clinical practice over the last decade and the launches of efficacious, premium-priced agents are set to drive market expansion through 2024. Despite these advances, untapped market potential remains for agents that can improve the prognosis and overall survival compared with currently available agents.

Login to access report

launch Related Market Assessment Reports